Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1995 1
1996 2
1997 2
1998 1
1999 1
2000 2
2002 1
2004 1
2007 3
2008 4
2009 5
2010 2
2011 5
2012 2
2014 3
2015 4
2016 4
2017 4
2018 3
2019 3
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, De Laurentiis M, Gravina A, Bisagni G, Rimanti A, Turletti A, Nisticò C, Vaccaro A, Cognetti F, Fabi A, Gasparro S, Garrone O, Alicicco MG, Urracci Y, Mansutti M, Poletti P, Correale P, Bighin C, Puglisi F, Montemurro F, Colantuoni G, Lambertini M, Boni L; Gruppo Italiano Mammella Investigators. Del Mastro L, et al. Lancet Oncol. 2022 Dec;23(12):1571-1582. doi: 10.1016/S1470-2045(22)00632-5. Epub 2022 Nov 10. Lancet Oncol. 2022. PMID: 36370716 Clinical Trial.
Knowledge about cancer screening programmes in Sardinia.
Mereu A, Concu F, Dessì C, Girau M, Ionta MT, Lai L, Liori A, Masala M, McGilliard CD, Origa P, Piazza MF, Pisanu L, Soggiu B, Sotgiu A, Contu P, Sardu C. Mereu A, et al. Among authors: ionta mt. J Prev Med Hyg. 2019 Dec 20;60(4):E337-E342. doi: 10.15167/2421-4248/jpmh2019.60.4.1094. eCollection 2019 Dec. J Prev Med Hyg. 2019. PMID: 31967090 Free PMC article.
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review.
Airoldi M, Amadori D, Barni S, Cinieri S, De Placido S, Di Leo A, Gennari A, Iacobelli S, Ionta MT, Lorusso V, Lotrionte M, Marchetti P, Mattioli R, Minotti G, Pronzato P, Rosti G, Tondini CA, Veronesi A. Airoldi M, et al. Among authors: ionta mt. Tumori. 2011 Nov-Dec;97(6):690-2. doi: 10.1177/030089161109700602. Tumori. 2011. PMID: 22322832 Review.
Predictive factors for 6 vs 12 cycles of Folfiri-Bevacizumab in metastatic colorectal cancer.
Formica V, Ionta MT, Massidda B, Vessia G, Maiorino L, Casaretti R, Natale D, Barberis G, Filippelli G, Greco E, Blasi L, Mancarella S, Russo A, Barbato E, Lullo LD, Roselli M. Formica V, et al. Among authors: ionta mt. Oncotarget. 2017 Dec 17;9(2):2876-2886. doi: 10.18632/oncotarget.23355. eCollection 2018 Jan 5. Oncotarget. 2017. PMID: 29416820 Free PMC article.
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.
Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Magnani M. Ruzzo A, et al. Among authors: ionta mt. Sci Rep. 2019 Aug 8;9(1):11527. doi: 10.1038/s41598-019-47627-1. Sci Rep. 2019. PMID: 31395900 Free PMC article. Clinical Trial.
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.
Rosati G, Lonardi S, Galli F, Di Bartolomeo M, Ronzoni M, Zampino MG, Banzi M, Zaniboni A, Pasini F, Bozzarelli S, Garattini SK, Ferrari D, Montesarchio V, Mambrini A, Ciuffreda L, Galli F, Pusceddu V, Carlomagno C, Bidoli P, Amoroso D, Bochicchio AM, Frassineti L, Corsi D, Bilancia D, Pastorino A, De Stefano A, Labianca R; TOSCA (Three or Six Colon Adjuvant) investigators. Rosati G, et al. Eur J Cancer. 2021 May;148:190-201. doi: 10.1016/j.ejca.2021.01.051. Epub 2021 Mar 18. Eur J Cancer. 2021. PMID: 33744715
Genome-wide association study of susceptibility loci for breast cancer in Sardinian population.
Palomba G, Loi A, Porcu E, Cossu A, Zara I, Budroni M, Dei M, Lai S, Mulas A, Olmeo N, Ionta MT, Atzori F, Cuccuru G, Pitzalis M, Zoledziewska M, Olla N, Lovicu M, Pisano M, Abecasis GR, Uda M, Tanda F, Michailidou K, Easton DF, Chanock SJ, Hoover RN, Hunter DJ, Schlessinger D, Sanna S, Crisponi L, Palmieri G. Palomba G, et al. Among authors: ionta mt. BMC Cancer. 2015 May 10;15:383. doi: 10.1186/s12885-015-1392-9. BMC Cancer. 2015. PMID: 25956309 Free PMC article.
Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma.
Palomba G, Cossu A, Paliogiannis P, Pazzola A, Baldino G, Scartozzi M, Ionta MT, Ortu S, Capelli F, Lanzillo A, Sedda T, Sanna G, Barca M, Virdis L, Budroni M, Palmieri G. Palomba G, et al. Among authors: ionta mt. Oncol Lett. 2016 Aug;12(2):1415-1421. doi: 10.3892/ol.2016.4798. Epub 2016 Jun 29. Oncol Lett. 2016. PMID: 27446446 Free PMC article.
Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Generali D, Montemurro F, Bordonaro R, Mafodda A, Romito S, Michelotti A, Piovano P, Ionta MT, Bighin C, Sartori D, Frassoldati A, Cazzaniga ME, Riccardi F, Testore F, Vici P, Barone CA, Schirone A, Piacentini F, Nolè F, Molino A, Latini L, Simoncini EL, Roila F, Cognetti F, Nuzzo F, Foglietta J, Minisini AM, Goffredo F, Portera G, Ascione G, Mariani G. Generali D, et al. Among authors: ionta mt. Oncologist. 2017 Jun;22(6):648-654. doi: 10.1634/theoncologist.2016-0461. Epub 2017 Apr 21. Oncologist. 2017. PMID: 28432226 Free PMC article. Clinical Trial.
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group. De Giorgi U, et al. BJU Int. 2019 Jan;123(1):98-105. doi: 10.1111/bju.14461. Epub 2018 Jul 23. BJU Int. 2019. PMID: 29956884 Free article.
54 results